BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26045280)

  • 1. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
    Trauner M; Halilbasic E; Claudel T; Steinacher D; Fuchs C; Moustafa T; Pollheimer M; Krones E; Kienbacher C; Traussnigg S; Kazemi-Shirazi L; Munda P; Hofer H; Fickert P; Paumgartner G
    Dig Dis; 2015; 33(3):433-9. PubMed ID: 26045280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Halilbasic E; Steinacher D; Trauner M
    Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Steinacher D; Claudel T; Trauner M
    Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.
    Hofmann AF; Zakko SF; Lira M; Clerici C; Hagey LR; Lambert KK; Steinbach JH; Schteingart CD; Olinga P; Groothuis GM
    Hepatology; 2005 Dec; 42(6):1391-8. PubMed ID: 16317695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
    Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
    Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
    Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
    J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
    Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
    Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
    Cabrera D; Arab JP; Arrese M
    Handb Exp Pharmacol; 2019; 256():237-264. PubMed ID: 31236688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
    van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
    Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
    Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
    J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
    Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
    Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ursodeoxycholic acid as the main treatment of hepatobiliary diseases in children and teenagers].
    Reĭzis AR; Nikitina TS; Drondina AK; Anan'eva NP; Stulov AP
    Ross Gastroenterol Zh; 2001; (1):86-91. PubMed ID: 11565130
    [No Abstract]   [Full Text] [Related]  

  • 17. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
    Lazaridis KN; Gores GJ; Lindor KD
    J Hepatol; 2001 Jul; 35(1):134-46. PubMed ID: 11495032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
    Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
    J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice.
    Truong JK; Li J; Li Q; Pachura K; Rao A; Gumber S; Fuchs CD; Feranchak AP; Karpen SJ; Trauner M; Dawson PA
    JCI Insight; 2023 Mar; 8(6):. PubMed ID: 36787187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.